CAR-T Cell Therapy for Solid Tumors

CAR-T therapy delivers remission rates above 80 percent in blood cancers. The frontier is solid tumors making up 90 percent of cancer deaths. New strategies with IL-18 payloads and TIL therapies show Phase 1 signals in breast and lung cancers. Iovance lifileucel received FDA approval for melanoma in 2024. By 2030 analysts project at least 3 solid tumor CAR-T approvals representing a potential cure pathway.